LLY (Eli Lilly and Co) Cash Receipts from Tax Refunds


LLY Eli Lilly and Co LLY
98 GF Score
Price $1,105.78
GF Value $1,407.82
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Eli Lilly and Co Cash Receipts from Tax Refunds?

Cash Receipts from Tax Refunds only applicable to companies reporting Cash Flow from Operations in direct method.

LLY
98GF Score
Eli Lilly and Co LLY
Cash Receipts from Tax Refunds is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of $1,105.78 is trading 21.5% below its estimated GF Value™ of $1,407.82. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for LLY:

  • Cash Receipts from Tax Refunds:
  • GF Value™: $1,407.82 vs. price of $1,105.78 (21.5% below fair value)
  • GF Score™: 98/100 with 5 warning signs

No single metric tells the full story. See the LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
98GF Score

Get the complete analysis for LLY

Cash Receipts from Tax Refunds is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1,105.78
Price
$1,407.82
GF Value